All In Biotech

Free tool

FAERS Monitor: Xalkori

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217581 or its brand name (Xalkori, Crizotinib). Reports on generic versions are filed under their own applications.

Reports

12,739

Serious

9,350

73% of reports

Hospitalization

3,085

Death reported

3,853

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death2,379
  • disease progression1,217
  • nausea1,124
  • neoplasm progression1,110
  • diarrhoea849
  • vomiting799
  • fatigue557
  • off label use474
  • oedema peripheral449
  • constipation442
  • dyspnoea432
  • lung neoplasm malignant420
  • visual impairment406
  • decreased appetite383
  • asthenia345

Reports by year received

View as table
YearReports
2011109
2012774
20131,097
20141,298
20151,195
20161,140
20171,012
20181,024
20191,074
2020813
2021661
2022660
2023629
2024587
2025407
2026259

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,420 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neoplasm progressionSignal1,11054.451.456,395
disease progressionSignal1,21717.116.318,403
lung neoplasm malignantSignal42017.015.56,272
oedema peripheralSignal4496.15.61,914
visual impairmentSignal4065.44.91,464
deathSignal2,3794.64.46,893
constipationSignal4423.43.1733
vomitingSignal7992.82.6949
decreased appetiteSignal3832.72.5421
nauseaSignal1,1242.32.2900
diarrhoeaSignal8492.22.0553
asthenia3451.51.461
dyspnoea4321.31.124
fatigue5571.21.116
off label use4740.90.86

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.